Phaseline

Targets › EDNRA

EDNRA (Endothelin-1 receptor): drug programs, companies and trials

8 programs from 8 companies in 20 trials: 9 Phase 3, 8 Phase 2, 3 Phase 4; Genitourinary, Cardiovascular, Neurology; next expected readout Jan 2027.

Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P25101)

Open in Phaseline: the race on EDNRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Travere TherapeuticsSparsentan
Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist
EDNRA, AGTR1Phase 4Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated VasculitisMar 2027
Johnson & Johnson (Janssen)Macitentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 3Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary HypertensionJan 2027
University Hospital, Grenoblebosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 3Ischemic Optic NeuropathyFeb 2027
AstraZenecaZibotentan
Endothelin receptor ET-A antagonist
EDNRAPhase 3Chronic Kidney Disease With High ProteinuriaFeb 2027
NovartisAtrasentan
Endothelin receptor ET-A antagonist
EDNRAPhase 3IgA Nephropathy; Berger DiseaseApr 2028
University of EdinburghBosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Large Vessel VasculitisJul 2027
Noorik BiopharmaceuticalsAmbrisentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH)–
University Hospital, RouenBosentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Resistant Hypertension–

Conditions

IgA Nephropathy (3) Immunoglobulin A Nephropathy (2) Chronic Kidney Disease With High Proteinuria (2) Hypertension, Pulmonary (2) Ischemic Optic Neuropathy (1) Berger Disease (1) Proteinuria (1) Focal Segmental Glomerulosclerosis (1) ANCA Associated Vasculitis (1) Hepatorenal Syndrome (1) Pulmonary Arterial Hypertension (PAH) (1) Resistant Hypertension (1)

Modalities

small molecule (7), mixed (1)

Companies

University Hospital, Grenoble (1) Novartis (1) Travere Therapeutics (1) AstraZeneca (1) Noorik Biopharmaceuticals (1) University Hospital, Rouen (1) University of Edinburgh (1) Johnson & Johnson (Janssen) (1)

Related targets

EDNRB (5) AGTR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.